Portfolio Update: Annexon (ANNX), AtriCure (ATRC)
Annexon, Inc. (NASDAQ:ANNX) and AtriCure, Inc. (NASDAQ:ATRC) recently delayed the [...]
Arc-7 trial results positive for Arcus; SanaCurrents closing out coverage
Arcus Biosciences, Inc., (NASDAQ:RCUS) reported the first interim analysis of [...]
Tarsus shares up in pre-market trading after impressive Phase IIb/III results
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) said prior to the opening of [...]
SanaCurrents closing out coverage of Magenta Therapeutics (MGTA), Verona Pharma (VRNA)
Magenta Therapeutics (NASDAQ:MGTA) reported this month that all multiple myeloma [...]
FDA approves Scynexis’ (SCYX) ibrexafungerp
Before the market opened on June 2, Scynexis (NASDAQ:SCYX) announced [...]
June 1 PDUFA decision for Scynexis (SCYX) to be followed by catalysts from MGTA, RCUS, PLRX
The FDA plans to decide on June 1, 2021, if [...]
SanaCurrents Portfolio Update: Acutus, Atara, Summit, Verona
The catalyst-driven model of SanaCurrents cannot be realized if management [...]
Adverse events appear to hold back positive Scholar Rock data; SanaCurrents closing out coverage
Scholar Rock Holding Corp. (NASDAQ:SRRK) reported positive topline data from [...]